Seaport Therapeutics reports Q3 2026 results, two Phase 2 programs advancing

Seaport Therapeutics announced third-quarter 2026 financial results on November 2, 2026, alongside updates on its two lead neuropsychiatric programs.

The company ran a randomized, double-blind, placebo-controlled Phase 1 trial testing multiple dose levels of GlyphAllo on simulated driving performance in healthy volunteers, and the trial met its primary endpoint: an evening dose of 375 mg GlyphAllo did not impair next-morning driving performance versus placebo on Day 5 after multiple days of dosing.¹ A secondary endpoint was also met, with a single 250 mg evening dose showing no impairment versus placebo on Day 2, and the drug was reported as well tolerated with no serious adverse events.¹ Seaport said it plans to submit these results to the FDA as part of GlyphAllo's ongoing development program.¹

Separately, Seaport is enrolling patients in BUOY-1, a two-arm, global, randomized, double-blind, placebo-controlled Phase 2b trial of GlyphAllo in major depressive disorder with or without anxious distress, with topline data expected in the first half of 2027.¹

For GlyphAgo, the company dosed its first patient in October in a Phase 2a proof-of-pharmacology trial testing 16 mg/day and 32 mg/day doses in patients with generalized anxiety disorder and sleep disturbance, assessing sleep outcomes including the Insomnia Severity Index and EEG measures.¹ Topline data from this trial are expected in early 2028.¹ Seaport also plans to begin a global, randomized, double-blind, placebo-controlled Phase 2/3 trial of GlyphAgo in GAD in the first half of 2027, with topline results expected by year-end 2028.¹

On finances, Seaport held $403.8 million in cash, cash equivalents, and investments as of September 30, 2026, which it said is expected to support operations into 2029.¹ Net loss for the quarter was $26.4 million, compared with $22.5 million in the same period of 2025.¹